Immune response from STRIDE, a randomized, Phase II, open-label study of sipuleucel-T sip-T with concurrent vs sequential enzalutamide enz administration in metastatic castration-resistant prostate cancer mCRPCReportar como inadecuado




Immune response from STRIDE, a randomized, Phase II, open-label study of sipuleucel-T sip-T with concurrent vs sequential enzalutamide enz administration in metastatic castration-resistant prostate cancer mCRPC - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Journal for ImmunoTherapy of Cancer

, 3:P145

First Online: 04 November 2015DOI: 10.1186-2051-1426-3-S2-P145

Cite this article as: Drake, C.G., Quinn, D., Dreicer, R. et al. j. immunotherapy cancer 2015 3Suppl 2: P145. doi:10.1186-2051-1426-3-S2-P145 Download fulltext PDF



Autor: Charles G Drake - David Quinn - Robert Dreicer - Emmanuel Antonarakis - Neal Shore - John Corman - Raoul Concepcion - Chri

Fuente: https://link.springer.com/



DESCARGAR PDF




Documentos relacionados